Answers are grounded in this paper and cite their sources.
Coronavirus disease 2019 (COVID-19) is overshadowing society across the world, and it will redefine many aspects of how we live and work in the future. In a crisis, people are rightly looking for solutions from their leaders and experts, and their response and actions will define them for years to come. COVID-19 may also be such a defining moment for clinical pharmacology in terms of its role in drug development and therapy. The recent reviews published in this journal of the clinical pharmacology of azithromycin8 and favipiravir9 as potential COVID-19 therapies are examples of how Clinical Pharmacology & Therapeutics (CPT) aims to contribute to the rapid dissemination of such critical information and knowledge. In addition, rational dosing regimens developed for other infectious diseases may inform best clinical practice for repurposing in COVID-19 research.10 As a next step, knowledge gained about potentially effective COVID-19 therapies can be integrated very rapidly in quantitative pharmacology models, which in turn can be used to simulate and optimize trials (including guiding selection and timing of informative biomarkers) and to rationalize and personalize dosing in patients. New data can be integrated immediately to update and improve the model in a rapid-turnaround version of Sheiner’s (1997)11 “learn-and-confirm” cycle. One of the first examples of such an approach published in CPT is the work by Garcia-Cremades et al.12 who developed a model integrating historical and emerging preclinical and clinical pharmacokinetic, virologic, and safety data to optimize hydroxychloroquine dosing in COVID-19 patients. As pointed out by the authors, there are obvious limitations associated with their work, in particular that at the time of publication the evidence for the actual efficacy of hydroxychloroquine or any other pharmacological treatment against COVID-19 was limited at best. However, clinical pharmacologists are very well positioned to handle this inevitable uncertainty in the best possible scientific and transparent manner. The use of models allows for integration of all available information from various sources, makes all assumptions transparent and explicit, and provides a framework to quantify uncertainty. The key conclusion that can be made from the work by Garcia-Cremades12 and coworkers is that dosing regimens for hydroxychloroquine used in other indications are unlikely to work in COVID-19. Therefore, we believe that reports such as the recent one from Magagnoli et al.13 about the apparent lack of efficacy of repurposed drugs need to be interpreted with caution and with expert clinical pharmacology input. As illustrated by the work of Garcia-Cremades et al.,12 not only has the COVID-19 pandemic drawn the attention of the scientific community to research in clinical pharmacology, the pandemic has presented new opportunities to advance research in all aspects of our discipline. For example, clinical pharmacologists have been leaders in clinical trial design, including use of Bayesian methods and most recently the incorporation of multiple data types, such as real-world data in drug development and approval.14, 15 The pandemic presents a unique opportunity to advance the sciences of clinical trial design with a focus, as noted above, on trials for rapidly progressing infections and for which real-world data should be integrated into the trial design. Discovery and use of novel biomarkers and other surrogate end points are needed in the case of a new infectious agent such as COVID-19, which has a distinct clinical presentation and is associated with unique clinical sequalae, such as ARDS. Indeed, the need for continued biomarker discovery, validation, and use has been highlighted in several recent manuscripts in the journal.16, 17 Moreover, complications associated with COVID-19, such as microbial superinfections, ARDS, and renal failure occur quickly, progress rapidly, and are associated with high mortality rates. These comorbidities require rapid evaluation and treatment, presenting further opportunities to advance clinical trial design, biomarker discovery, and the use of surrogate end points. Real-world data from the electronic health record (EHR) have increasingly been used in pharmacoepidemiology and pharmacovigilance to monitor drug utilization patterns, as well as the efficacy and safety of drugs in large patient populations. Importantly, a recent commentary in CPT from European regulators describes the tremendous opportunities for learning about drug efficacy and toxicity from data in the EHR and highlights various initiatives that are focused on bringing real-world data to a level of acceptability by regulatory authorities.15 Similarly, Xu et al.18 provide a timely review of current status, challenges, and future directions for EHRs in drug repurposing. New resources and databases such as the Johns Hopkins Center for Systems Science and Engineering are being developed and made available to researchers (see https://cloud.google.com/blog/products/data-analytics/free-public-datasets-for-covid19). These resources and others present unprecedented opportunities for using real-world data in pharmacoepidemiologic studies, for drug repurposing, and to discover and probe the mechanisms of adverse drug reactions, drug–drug interactions, and many aspects of therapeutic drug use in a real-world setting. Pharmacogenomics and precision medicine, important areas of clinical pharmacology, have made great strides in the past decade, spanning the translational gap from research to patient care. A recent manuscript in CPT describes the myriad of resources that enable research and implementation in pharmacogenomics, including resources provided by the Pharmacogene Variation Consortium (PharmVar),19 the Pharmacogenomics Knowledgebase (PharmGKB),20 and the Clinical Pharmacogenetic Implementation Consortium (CPIC).21 COVID-19 provides opportunities to expand research in pharmacogenomics and implementation of genetic testing in patient care. Notably, PharmGKB has established web pages focused on COVID-19 at the interface of pharmacogenetics (see https://www.pharmgkb.org/disease/PA166197121/overview). These pages will be populated with information on pharmacogenetic variants that are associated with therapeutic or adverse response to the drugs being tested and used in COVID19 as well as the pathways involved in the pharmacokinetics and pharmacodynamics of these drugs. Therapeutic and adverse response to several of the drugs being used or tested for COVID-19 is associated with genetic variants in enzymes, transporters, and channels, and those associations present new opportunities for implementation of pharmacogenetic testing and research. Finally, drug repurposing and clinical trials for COVID-19 present an opportunity for integration of multiple data types (multi-omics) to robustly understand and predict both therapeutic and adverse drug response. Though there is tremendous opportunity for clinical pharmacology to learn and confirm, there is also a danger of publishing poor quality or misleading research results. Clinical pharmacology is in a defining moment, and we are being scrutinized as never before. The peer-review process must not fail during this time. High standards in reviewing and evaluating the plethora of manuscripts that each journal receives must be rigorously maintained by reviewers and editors for all journals, including CPT, to maintain the trust of the scientific community at large as well as the general public. We are therefore very pleased to announce that we have strengthened the CPT Editorial Team in the area of infectious diseases by the appointment of Dr Joseph Standing from the Department of Infection, Immunity, & Inflammation, University College London. He has an outstanding track record in the development and application of quantitative pharmacology approaches in antiviral and immunological clinical research and is actively involved in the design and analysis of COVID-19 trials.22 What will also not be affected by COVID-19 is CPT’s mission to be the leading journal for clinical pharmacology and therapeutic innovations, transforming the development and utilization of medicines across all diseases), as demonstrated by the range of topics covered in this issue. The COVID-19 pandemic can be a defining moment for clinical pharmacology, and there is no reason to think that the discipline is not ready to meet the challenge. As the leading journal in the field, CPT will facilitate the implementation and demonstration of the discipline’s leadership through the rapid publication and broad dissemination of the highest quality and most impactful science and clinical applications. The ASCPT Journal Family is proud to provide a cross-journal Virtual Issue (https://ascpt.onlinelibrary.wiley.com/covid-19) compiling the COVID-19 research published in CPT, Clinical and Translational Science, and CPT: Pharmacometrics & Systems Pharmacology. Here you can access all of the COVID-19 research published in the ASCPT Journal Family, and appreciate the full scope of what clinical pharmacologists are discovering about this disease and the potential tools to fight it.
No takes yet. Share an insight, caveat, or question.
Graaf et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: